Company Quick10K Filing
Pharmagreen Biotech
Price-0.00 EPS-0
Shares365 P/E0
MCap-0 P/FCF0
Net Debt-0 EBIT-1
TEV-0 TEV/EBIT0
TTM 2019-09-30, in MM, except price, ratios
10-Q 2020-12-31 Filed 2021-02-22
10-K 2020-09-30 Filed 2021-01-08
10-Q 2020-06-30 Filed 2020-08-19
S-1 2020-05-08 Public Filing
10-Q 2020-03-31 Filed 2020-05-19
10-Q 2019-12-31 Filed 2020-02-18
10-Q 2019-06-30 Filed 2019-08-19
S-1 2019-03-20 Public Filing
8-K 2020-10-19
8-K 2020-10-14
8-K 2020-08-07
8-K 2020-07-21
8-K 2020-05-22
8-K 2020-02-28
8-K 2020-01-23
8-K 2019-11-29
8-K 2019-11-08
8-K 2019-09-11

PHBI 8K Current Report

Item 8.01 Other Events.

Pharmagreen Biotech Report 2020-10-19

8-K 1 8kpbi.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 19, 2020

 

Pharmagreen Biotech Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

 

333-151350

 

26-1679929

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

  

2987 Blackbear Court, Coquitlam, British Columbia, V3E 3A2 

(Address of Principal Executive Offices) (Zip Code) 

 

702-803-9404 

(Registrant's telephone number, including area code)

 

_______________________________________________ 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares

PHBI

OTC Markets

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company [ ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]


Item 8.01 Other Events.

On October 19, 2020, Pharmagreen Biotech Inc. announced that it is no longer under chapter 11 proceedings of the U.S. Bankruptcy Code. On August 11, 2020, the Company voluntarily filed for petitions for relief under chapter 11.  On October 09, 2020, a stay order was lifted by a United States District Judge of the United States District Court for the Southern District of New York, on an action filed by EMA Financial LLC. The company does not plan to appeal this ruling.  This effectively removed the company from its Chapter 11 bankruptcy proceedings and protection.   

.

 SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

Pharmagreen Biotech Inc.

 

 

 

 

 

Dated: October 19, 2020

By:

/s/ Peter Wojcik

 

 

 

Peter Wojcik

 

 

 

Chief Executive Officer, Director